Skip to main content
Top
Published in: Neurological Research and Practice 1/2022

Open Access 01-12-2022 | Breast Cancer | Review

Anti-SEZ6L2 antibodies in paraneoplastic cerebellar syndrome: case report and review of the literature

Authors: Annika Kather, Florian Holtbernd, Robert Brunkhorst, Dimah Hasan, Robert Markewitz, Klaus-Peter Wandinger, Martin Wiesmann, Jörg B. Schulz, Simone C. Tauber

Published in: Neurological Research and Practice | Issue 1/2022

Login to get access

Abstract

Seizure Related 6 Homolog Like 2 (SEZ6L2) protein has been shown to have implications in neuronal and especially motor function development. In oncology, overexpression of SEZ6L2 serves as a negative prognostic marker in several tumor entities. Recently, few cases of anti-SEZ6L2 antibody mediated cerebellar syndromes were reported. In this article, we present a case of a 70-year-old woman with subacute onset of gait disturbance, dysarthria and limb ataxia. Serum anti-SEZ6L2 antibodies were markedly increased, and further diagnostic workup revealed left sided breast cancer. Neurological symptoms and SEZ6L2 titer significantly improved after curative tumor therapy. This is a very rare and educationally important report of anti-SEZ6L2 autoimmune cerebellar syndrome with a paraneoplastic etiology. Additionally, we performed a review of the current literature for SEZ6L2, focusing on comparing the published cases on autoimmune cerebellar syndrome.
Literature
1.
go back to reference Uy, C. E., Binks, S., & Irani, S. R. (2021). Autoimmune encephalitis: Clinical spectrum and management. Practical Neurology, 21, 412–423.CrossRef Uy, C. E., Binks, S., & Irani, S. R. (2021). Autoimmune encephalitis: Clinical spectrum and management. Practical Neurology, 21, 412–423.CrossRef
2.
go back to reference Thaler, F. S., et al. (2021). Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: Real-world evidence from the GENERATE Registry. Neurology Neuroimmunology Neuroinflammation, 8, e1088.CrossRef Thaler, F. S., et al. (2021). Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: Real-world evidence from the GENERATE Registry. Neurology Neuroimmunology Neuroinflammation, 8, e1088.CrossRef
3.
go back to reference Nosadini, M., et al. (2021). Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: A meta-analysis. JAMA Neurology, 78, 1333–1344.CrossRef Nosadini, M., et al. (2021). Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: A meta-analysis. JAMA Neurology, 78, 1333–1344.CrossRef
4.
go back to reference Shimizu-Nishikawa, K., Kajiwara, K., Kimura, M., Katsuki, M., & Sugaya, E. (1995). Cloning and expression of SEZ-6, a brain-specific and seizure-related cDNA. Molecular Brain Research, 28, 201–210.CrossRef Shimizu-Nishikawa, K., Kajiwara, K., Kimura, M., Katsuki, M., & Sugaya, E. (1995). Cloning and expression of SEZ-6, a brain-specific and seizure-related cDNA. Molecular Brain Research, 28, 201–210.CrossRef
5.
go back to reference Yaguchi, H., et al. (2018). Anti-Sez6l2 antibody detected in a patient with immune-mediated cerebellar ataxia inhibits complex formation of GluR1 and Sez6l2. Journal of Neurology, 265, 962–965.CrossRef Yaguchi, H., et al. (2018). Anti-Sez6l2 antibody detected in a patient with immune-mediated cerebellar ataxia inhibits complex formation of GluR1 and Sez6l2. Journal of Neurology, 265, 962–965.CrossRef
6.
go back to reference Yaguchi, H., et al. (2017). Sez6l2 regulates phosphorylation of ADD and neuritogenesis. Biochemical and Biophysical Research Communications, 494, 234–241.CrossRef Yaguchi, H., et al. (2017). Sez6l2 regulates phosphorylation of ADD and neuritogenesis. Biochemical and Biophysical Research Communications, 494, 234–241.CrossRef
7.
go back to reference Boonen, M., et al. (2016). Cathepsin D and its newly identified transport receptor SEZ6L2 can modulate neurite outgrowth. Journal of Cell Science, 129, 557–568.PubMed Boonen, M., et al. (2016). Cathepsin D and its newly identified transport receptor SEZ6L2 can modulate neurite outgrowth. Journal of Cell Science, 129, 557–568.PubMed
8.
go back to reference Konyukh, M., et al. (2011). Variations of the candidate SEZ6L2 gene on Chromosome 16p11.2 in patients with autism spectrum disorders and in human populations. PLoS ONE, 6, e17289.CrossRef Konyukh, M., et al. (2011). Variations of the candidate SEZ6L2 gene on Chromosome 16p11.2 in patients with autism spectrum disorders and in human populations. PLoS ONE, 6, e17289.CrossRef
9.
go back to reference Maccarrone, G., et al. (2013). Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. Journal of Psychiatric Research, 47, 1572–1580.CrossRef Maccarrone, G., et al. (2013). Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. Journal of Psychiatric Research, 47, 1572–1580.CrossRef
10.
go back to reference Ishikawa, N., et al. (2006). Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Science, 97, 737–745.CrossRef Ishikawa, N., et al. (2006). Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Science, 97, 737–745.CrossRef
11.
go back to reference Chen, L., Han, S., Li, Y., Zheng, Y., & Zhang, Q. (2022). SEZ6L2, regulated by USF1, accelerates the growth and metastasis of breast cancer. Experimental Cell Research, 417, 113194.CrossRef Chen, L., Han, S., Li, Y., Zheng, Y., & Zhang, Q. (2022). SEZ6L2, regulated by USF1, accelerates the growth and metastasis of breast cancer. Experimental Cell Research, 417, 113194.CrossRef
12.
go back to reference Yu, Z., Du, M., & Lu, L. (2022). A novel 16-genes signature scoring system as prognostic model to evaluate survival risk in patients with glioblastoma. Biomedicines, 10, 317.CrossRef Yu, Z., Du, M., & Lu, L. (2022). A novel 16-genes signature scoring system as prognostic model to evaluate survival risk in patients with glioblastoma. Biomedicines, 10, 317.CrossRef
13.
go back to reference Wang, Z., et al. (2020). Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma. Translational Cancer Research, 9, 6768–6779.CrossRef Wang, Z., et al. (2020). Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma. Translational Cancer Research, 9, 6768–6779.CrossRef
14.
go back to reference Dufresne, J., et al. (2018). The plasma peptides of ovarian cancer. Clinical Proteomics, 15, 41.CrossRef Dufresne, J., et al. (2018). The plasma peptides of ovarian cancer. Clinical Proteomics, 15, 41.CrossRef
15.
go back to reference Lee, J.-S., et al. (2020). SEZ6L2 is an important regulator of drug-resistant cells and tumor spheroid cells in lung adenocarcinoma. Biomedicines, 8, 500.CrossRef Lee, J.-S., et al. (2020). SEZ6L2 is an important regulator of drug-resistant cells and tumor spheroid cells in lung adenocarcinoma. Biomedicines, 8, 500.CrossRef
16.
go back to reference Yaguchi, H., et al. (2014). Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. Journal of Neurology, 261, 224–226.CrossRef Yaguchi, H., et al. (2014). Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. Journal of Neurology, 261, 224–226.CrossRef
17.
go back to reference Borsche, M., et al. (2019). Sez6l2-antibody-associated progressive cerebellar ataxia: A differential diagnosis of atypical parkinsonism. Journal of Neurology, 266, 522–524.CrossRef Borsche, M., et al. (2019). Sez6l2-antibody-associated progressive cerebellar ataxia: A differential diagnosis of atypical parkinsonism. Journal of Neurology, 266, 522–524.CrossRef
18.
go back to reference Landa, J., et al. (2021). Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurology-Neuroimmunology Neuroinflammation, 8, e916.CrossRef Landa, J., et al. (2021). Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurology-Neuroimmunology Neuroinflammation, 8, e916.CrossRef
19.
go back to reference Reis Carneiro, D., Maresch, Â., Cunha, R., & Morgadinho, A. (2022). Sez6l2-associated encephalitis in a patient with small-cell lung cancer. Neurological sciences: Official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. https://doi.org/10.1007/s10072-022-06244-zCrossRef Reis Carneiro, D., Maresch, Â., Cunha, R., & Morgadinho, A. (2022). Sez6l2-associated encephalitis in a patient with small-cell lung cancer. Neurological sciences: Official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. https://​doi.​org/​10.​1007/​s10072-022-06244-zCrossRef
20.
go back to reference Mehdiyeva, A., Hietaharju, A., & Sipilä, J. (2022). SEZ6L2 antibody-associated cerebellar ataxia responsive to sequential immunotherapy. Neurology-Neuroimmunology Neuroinflammation, 9, e1131.CrossRef Mehdiyeva, A., Hietaharju, A., & Sipilä, J. (2022). SEZ6L2 antibody-associated cerebellar ataxia responsive to sequential immunotherapy. Neurology-Neuroimmunology Neuroinflammation, 9, e1131.CrossRef
21.
go back to reference Nash, A., et al. (2020). Lack of Sez6 family proteins impairs motor functions, short-term memory, and cognitive flexibility and alters dendritic spine properties. Cerebral Cortex, 1991(30), 2167–2184.CrossRef Nash, A., et al. (2020). Lack of Sez6 family proteins impairs motor functions, short-term memory, and cognitive flexibility and alters dendritic spine properties. Cerebral Cortex, 1991(30), 2167–2184.CrossRef
22.
go back to reference Torretta, E., et al. (2021). Novel insight in idiopathic normal pressure hydrocephalus (iNPH) biomarker discovery in CSF. International Journal of Molecular Sciences, 22, 8034.CrossRef Torretta, E., et al. (2021). Novel insight in idiopathic normal pressure hydrocephalus (iNPH) biomarker discovery in CSF. International Journal of Molecular Sciences, 22, 8034.CrossRef
23.
go back to reference Wang, N., et al. (2022). Identification of SMIM1 and SEZ6L2 as potential biomarkers for genes associated with intervertebral disc degeneration in pyroptosis. Disease Markers, 2022, 9515571.PubMedPubMedCentral Wang, N., et al. (2022). Identification of SMIM1 and SEZ6L2 as potential biomarkers for genes associated with intervertebral disc degeneration in pyroptosis. Disease Markers, 2022, 9515571.PubMedPubMedCentral
24.
go back to reference Kumar, R. A., et al. (2009). Association and mutation analyses of 16p11.2 autism candidate genes. PLoS ONE, 4, e4582.CrossRef Kumar, R. A., et al. (2009). Association and mutation analyses of 16p11.2 autism candidate genes. PLoS ONE, 4, e4582.CrossRef
25.
go back to reference Yu, Z.-L., et al. (2007). Febrile seizures are associated with mutation of seizure-related (SEZ) 6, a brain-specific gene. Journal of Neuroscience Research, 85, 166–172.CrossRef Yu, Z.-L., et al. (2007). Febrile seizures are associated with mutation of seizure-related (SEZ) 6, a brain-specific gene. Journal of Neuroscience Research, 85, 166–172.CrossRef
26.
go back to reference Mulley, J. C., et al. (2011). The role of seizure-related SEZ6 as a susceptibility gene in febrile seizures. Neurology Research International, 2011, 917565.CrossRef Mulley, J. C., et al. (2011). The role of seizure-related SEZ6 as a susceptibility gene in febrile seizures. Neurology Research International, 2011, 917565.CrossRef
27.
go back to reference Ambalavanan, A., et al. (2016). De novo variants in sporadic cases of childhood onset schizophrenia. European Journal of Human Genetics EJHG, 24, 944–948.CrossRef Ambalavanan, A., et al. (2016). De novo variants in sporadic cases of childhood onset schizophrenia. European Journal of Human Genetics EJHG, 24, 944–948.CrossRef
28.
go back to reference An, N., et al. (2020). SEZ6L2 knockdown impairs tumour growth by promoting caspase-dependent apoptosis in colorectal cancer. Journal of Cellular and Molecular Medicine, 24, 4223–4232.CrossRef An, N., et al. (2020). SEZ6L2 knockdown impairs tumour growth by promoting caspase-dependent apoptosis in colorectal cancer. Journal of Cellular and Molecular Medicine, 24, 4223–4232.CrossRef
29.
go back to reference Lu, J., & Chen, Q. (2021). Transcriptome-based identification of molecular markers related to the development and prognosis of Colon cancer. Nucleosides, Nucleotides & Nucleic Acids, 40, 1114–1124.CrossRef Lu, J., & Chen, Q. (2021). Transcriptome-based identification of molecular markers related to the development and prognosis of Colon cancer. Nucleosides, Nucleotides & Nucleic Acids, 40, 1114–1124.CrossRef
30.
go back to reference Luo, X., et al. (2022). High expression of SEZ6L2 as an independent prognostic Indicator in thyroid carcinoma. Gland Surgery, 11, 412–425.CrossRef Luo, X., et al. (2022). High expression of SEZ6L2 as an independent prognostic Indicator in thyroid carcinoma. Gland Surgery, 11, 412–425.CrossRef
31.
go back to reference Wang, L., et al. (2020). Upregulated seizure-related 6 homolog-like 2 is a prognostic predictor of hepatocellular carcinoma. Disease Markers, 2020, 7318703.CrossRef Wang, L., et al. (2020). Upregulated seizure-related 6 homolog-like 2 is a prognostic predictor of hepatocellular carcinoma. Disease Markers, 2020, 7318703.CrossRef
32.
go back to reference Wang, Q. (2017). CpG methylation patterns are associated with gene expression variation in osteosarcoma. Molecular Medicine Reports, 16, 901–907.CrossRef Wang, Q. (2017). CpG methylation patterns are associated with gene expression variation in osteosarcoma. Molecular Medicine Reports, 16, 901–907.CrossRef
33.
go back to reference Qiu, W. Q., et al. (2021). The Sez6 family inhibits complement by facilitating factor I cleavage of C3b and accelerating the decay of C3 convertases. Frontiers in Immunology, 12, 607641.CrossRef Qiu, W. Q., et al. (2021). The Sez6 family inhibits complement by facilitating factor I cleavage of C3b and accelerating the decay of C3 convertases. Frontiers in Immunology, 12, 607641.CrossRef
34.
go back to reference Hald, J., et al. (2012). Pancreatic islet and progenitor cell surface markers with cell sorting potential. Diabetologia, 55, 154–165.CrossRef Hald, J., et al. (2012). Pancreatic islet and progenitor cell surface markers with cell sorting potential. Diabetologia, 55, 154–165.CrossRef
35.
go back to reference Velasco, R., et al. (2021). Encephalitis induced by immune checkpoint inhibitors: A systematic review. JAMA Neurology, 78, 864–873.CrossRef Velasco, R., et al. (2021). Encephalitis induced by immune checkpoint inhibitors: A systematic review. JAMA Neurology, 78, 864–873.CrossRef
Metadata
Title
Anti-SEZ6L2 antibodies in paraneoplastic cerebellar syndrome: case report and review of the literature
Authors
Annika Kather
Florian Holtbernd
Robert Brunkhorst
Dimah Hasan
Robert Markewitz
Klaus-Peter Wandinger
Martin Wiesmann
Jörg B. Schulz
Simone C. Tauber
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Neurological Research and Practice / Issue 1/2022
Electronic ISSN: 2524-3489
DOI
https://doi.org/10.1186/s42466-022-00218-4

Other articles of this Issue 1/2022

Neurological Research and Practice 1/2022 Go to the issue